Original ArticleSerious adverse events attributed to REMIFENTANIL (cas 132875-61-7) patient-controlled analgesia during labour in The Netherlands

Add time:08/27/2019    Source:sciencedirect.com

BackgroundDuring labour, REMIFENTANIL (cas 132875-61-7) patient-controlled analgesia is used as an alternative to neuraxial analgesia. Remifentanil is associated with hypoventilation and respiratory depression but the frequency of serious maternal and neonatal adverse events is unknown. The aim of this study was to estimate the number of serious adverse events attributed to the use of remifentanil patient-controlled analgesia during labour in The Netherlands and to investigate the circumstances (e.g. monitoring, practice deviations) of these events and the subsequent management.

We also recommend Trading Suppliers and Manufacturers of REMIFENTANIL (cas 132875-61-7). Pls Click Website Link as below: cas 132875-61-7 suppliers

Prev:In vitro activities of ‘new’ and ‘conventional’ antibiotics against multidrug resistant Gram negative bacteria from patients in the intensive care unit
Next:Original ArticleREMIFENTANIL (cas 132875-61-7) patient-controlled analgesia in labour: six-year audit of outcome data of the RemiPCA SAFE Network (2010–2015))